Innovation in neuroscience drug discovery eBook

	Drug Discovery
	The latest drug discovery news from News Medical

Neuroscience drug discovery is evolving rapidly, driven by new technologies and fresh approaches at every research stage.

This eBook highlights recent breakthroughs in areas like Alzheimer’s, ALS, and neuroinflammation – offering expert insights and proven strategies to improve translational success. Learn how AI, biomarkers, and improved disease models are shaping more effective drug development. Download now to explore the future of neuroscience research.

Download the eBook

			CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, has introduced two new animal microphysiological system (MPS) models that enhance translatability in preclinical drug safety and toxicology assessments to its Contract Research Services (CRS).

			New open access tool could accelerate drug discovery Scientists at Northwestern University have developed the largest open-access resource of its kind to help researchers shave off months of early-stage drug development time by allowing them to better understand diseases and find potential treatments.

	Type 2 diabetes drug shows improvements for patients with progressive liver disease The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows improvements for patients with progressive liver disease, finds a clinical trial from China published by The BMJ today.

	Tagomics awarded £860 k Innovate UK Biomedical Catalyst grant for detection of colorectal cancer Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has been awarded £860 k Innovate UK funding as part of the Biomedical Catalyst program for the testing and development of innovative healthcare solutions from Innovate UK, the UK's innovation agency, with the remaining funding contributed by Tagomics.

	Nicotinamide riboside shows promise in treating Werner syndrome symptoms Werner syndrome (WS) is a rare genetic disorder that causes premature aging and serious complications. In the first clinical trial of its kind, researchers from Japan with the company Niagen Bioscience, investigated the effects of nicotinamide riboside (NR), a vitamin B3 derivative, in patients with WS.

	Prime Editing Enters the Clinic: A CRISPR Milestone for Rare Immune Disorders A new milestone for CRISPR: prime editing enters clinical trials, enabling precise, programmable DNA changes for treating rare genetic disorders like chronic granulomatous disease and sickle cell anemia.

	Weekly risperidone capsule delivers consistent drug levels for schizophrenia patients For many patients with schizophrenia, other psychiatric illnesses, or diseases such as hypertension and asthma, it can be difficult to take their medicine every day.

How would you rate today's newsletter?

Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney | Boston

Copyright © 2000-2025